Citations

Clear

3042 citation(s) found for "Kumar, S".

Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat
Utsuki, Tadanobu, Shoaib, Mohammed , Holloway, Harold W., Ingram, Donald K. , Wallace, William, Haroutunian, Vahram , Sambamurti, Kumar , Lahiri, Debomoy K. , Greig, Nigel H.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 4 | Issue: 5 | Pages: 405-415

10.3233/jad-2002-4507 | PMID 12446972 Get It

Lack of publication bias in randomized clinical trials (RCTs) sponsored by the National Cancer Institute (NCI) and performed by Cooperative Oncology Groups (COGs)
Daniels, Stephanie, Buckner, Jan C. , Swann, S., Smith, Roy E., Khyatat, A., Wells, Robert J., Djulbegović, Benjamin , Soares, Heloisa P. , Kumar, Ambuj , Daniels, S., Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6004-6004

10.1200/jco.2004.22.90140.6004 Get It

Osteosclerosis Secondary to Metastatic Oligodendroglioma
Maloney, Patrick R. , Yamaki, Vítor Nagai , Kumar, Ravi , Jentoft, Mark E. , Johnson, Derek, Hunt, Christopher , Clarke, Michelle, Johnson, Derek R. , Hunt, Christopher H. , Clarke, Michelle J.

Mayo Clinic

Rare Tumors | March 31, 2017 | Volume: 9 | Issue: 1 | Pages: 42-46

10.4081/rt.2017.6837 | PMID 28435646 Get It

This paper reviews a case of metastatic 1p/19q codeleted oligodendrioglioma causing diffuse osteosclerosis and pain. Primary central nervous system (CNS) tumors rarely metastasize outside the CNS, and metastatic oligodendroglioma is rarer still. The patient in this study had relief of pain after being treated with temozolomide. We discuss this rare presentation and potential treatment options, and review the literature in regards to metastatic oligodendrogliomas.
Treating Philadelphia chromosome/BCR‐ABL1 positive patients with Glivec (Imatinib mesylate): 10 years’ experience at Patan Hospital, Nepal
Kayastha, Gyan , Ranjitkar, Nora, Gurung, Radha, KC, Raj Kumar, Karki, Sanjit , Shrestha, Roshan , Thapa, Raj Kumar , Rajbhandari, Piyush , Poudyal, Buddhi, Acharya, Paras Kumar , Hayes, Bruce , Zimmerman, Mark, Mansfield, Aaron S. , Basnyat, Buddha , Mansfield, Aaron, Roberts, David J. , Mansfield, Aaron S

Mayo Clinic

British Journal of Haematology | March 29, 2017 | Volume: 177 | Issue: 6 | Pages: 991-999

10.1111/bjh.14645 | PMID 28369812 Get It

SummaryThe Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome/BCR‐ABL1 positive patients with chronic myeloid leukaemia (CML) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 CML patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty‐one patients were lost to follow‐up. We report on 180 CML patients with a median age of 38 years (range 9–81). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty‐nine of the 180 patients (77·2%) had at least one optimal response. Taken together, our cohort has a 95% overall survival rate and 78% of the patients were still taking Glivec at a median time of 48·8 months (range 3–140 months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21·7%). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for CML patients using tyrosine kinase inhibitors in resource‐poor settings.
Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer.
Zurita, Amado J. , Tu, Shi‐Ming, Araujo, John C. , Kim, Jeri , Wang, Jennifer , Efstathiou, Eleni , Pagliaro, Lance C. , Corn, Paul Gettys , Subudhi, Sumit Kumar , Tu, Shi‐Ming , Aparicio, Ana M , Logothetis, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 169-169

10.1200/jco.2017.35.6_suppl.169 Get It

169 Background: Cabozantinib (Cabo), a tyrosine kinase inhibitor of c-Met and VEGFR2, modulates the tumor microenvironment in a therapeutically favorable manner. We combined Cabo with androgen deprivation therapy (ADT) in patients (pts) with androgen-dependent metastatic prostate cancer (PCa) (NCT01630590). Methods: Pts received Cabo (starting dose 60 mg PO daily) and ADT with a GnRH analogue. Pts could receive up to 3 months of ADT prior to initiating Cabo. Bone scan (BS) and CT scans were performed every 12 weeks (wks). Efficacy endpoints included response in markers, BS and RECIST, and time to castrate-resistant progression defined by radiographic progression, clinical progression, or receipt of additional anti-cancer therapy. Results: From 01/27/2014 to 01/12/2016, 62 pts were enrolled: 94% (58/62) with bone metastasis, 56% (35/62) with measurable disease, 15% (9/62) with visceral involvement and 26% (16/62) with prior treatment of their primary tumor. 79% (49/62) of pts have high volume disease defined by > 4 bone lesions and/or involvement of viscera. Median time from start of ADT to start of Cabo was 3.4 wks. Improvements in BS were observed in 81% (44/54) of evaluable pts including complete responses (CR) in 15% (8/54). In evaluable pts with measurable disease, best response was stable disease in 9% (3/33), PR in 61% (20/33) and CR in 30% (10/33). Reductions in PSA > 90%, bone specific alkaline phosphatase > 50% and urine N-telopeptides > 50% occurred in 83% (50/60), 87% (34/39), 86% (19/22) of evaluable pts, respectively. With a median follow up of 21.4 months (mo), median PFS is 15.6 mo. Median duration of Cabo treatment is 13 mo. Most common toxicities are Grade 3 hypertension (16%), pulmonary embolus (6%), diarrhea (4%), fatigue (3%), nausea (3%), and deep venous thrombosis (3%) with no Grade 4 events. Cabo dose reductions to 40 and 20 mg occurred in 68% and 18% of pts, respectively, with discontinuations due to toxicity in 10% of pts. Conclusions: Cabo plus ADT has potent clinical activity in pts with high volume androgen-dependent PCa including improvements BS and reduction in markers of bone stromal function. Studies are underway to identify biomarkers predictive of best response. Clinical trial information: NCT01630590.
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
Sidana, Surbhi , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Kapoor, Prashant , Go, Ronald S. , Hwa, Yi L. , Leung, Nelson , Fonder, Amie , Hobbs, Miriam, Zeldenrust, Steven R., Russell, Stephen J. , Lust, John A., Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Go, Ronald S , Hwa, Yi Lisa, Leung, Nelson , Fonder, Amie L, Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Russell, Stephen J , Sidana, Surbhi , Dingli, David

Mayo Clinic

American Journal of Hematology | March 29, 2017 | Volume: 92 | Issue: 7 | Pages: 668-673

10.1002/ajh.24745 | PMID 28370486 Get It

Abstract We describe a series of 102 patients diagnosed from January 1, 1990 to December 31, 2015 with Type 1 monoclonal cryoglobulinemia (MoC). Symptoms were seen in 89 (87%) patients, including: cutaneous symptoms in 64 (63%) patients, with purpura (n = 43, 42%) and ulcers/gangrene (n = 35, 34%) being most common; neurological findings in 33 (32%) patients, most frequently sensory neuropathy (n = 24, 24%); vasomotor symptoms, mainly Raynaud's phenomenon in 25 (25%); arthralgias in 24 (24%); and renal manifestations, primarily glomerulonephritis in 14 (14%) patients. An underlying lymphoproliferative disorder was identified in 94 (92%) subjects; MGUS—39, myeloma—20, lymphoplasmacytic lymphoma—21 and others—14. Treatment was initiated in 73 (72%) patients, primarily for cryoglobulinemia‐related symptoms in 57. Treatment regimens consisted of: steroids ± alkylating agents in 29 (40%), novel myeloma therapies in 16 (22%), rituximab with alkylating agents in 12 (16%) and rituximab ± steroids in 11 (15%) patients; 22 patients received plasmapheresis. Six patients underwent autologous stem cell transplant. Cryocrit at treatment initiation, change in cryocrit and time to nadir cryocrit were predictive of symptom improvement. Treatment directed toward the underlying clonal disorder resulted in improvement (n = 47) or stabilization (n = 16) of symptoms in the majority of patients and disappearance of cryoglobulin in over one‐half.
Mid-treatment magnetic resonance imaging in pediatric intracranial low-grade gliomas treated with proton beam therapy
Kumar, Radhika , Rotondo, Ronny L. , Bradley, Julie A. , Vern-Gross, T.Z., Huh, Soon , Indelicato, Daniel J. , Vern-Gross, Tamara, Indelicato, Daniel J

Mayo Clinic

Acta Oncologica | March 24, 2017 | Volume: 56 | Issue: 9 | Pages: 1243-1247

10.1080/0284186x.2017.1306105 | PMID 28339304 Get It

Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis
Tandon, Nidhi , Sidana, Surbhi , Lacy, Martha Q. , Dingli, David , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Kumar, Shaji , Buadi, Francis K. , Fonder, Amie L, Hwa, Yi Lisa, Leung, Nelson , Go, Ronald S , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent , Russell, Stephen J , Sidana, Surbhi , Dingli, David

Mayo Clinic

American Journal of Hematology | March 17, 2017 | Volume: 92 | Issue: 6 | Pages: 549-554

10.1002/ajh.24723 | PMID 28314084 Get It

AbstractWe analyzed the outcomes following initial relapse or refractory disease in systemic light chain amyloidosis (AL) and the impact of type of therapy employed.A total of 1327 patients with AL seen at Mayo Clinic within 90 days of diagnosis, between 2006 and 2015, were reviewed. The study included 366 patients experiencing a documented hematological or organ relapse or refractory disease requiring start of second line therapy. Overall survival (OS) and time to next treatment (TTNT) were calculated from start of second line treatment.The median time to require second line treatment was 16.2 months (1‐93) from the start of first line therapy. At relapse, patients received proteasome inhibitors (PI; 45.1%), immunomodulators (IMiD; 22.7%), alkylators (9%), PI and IMiD combination (4.1%), autologous transplant (3.8%), steroids and other therapies (4.9%). Among these, 124 (33.9%) required change or reinstitution of therapy. The median time to require third line treatment was 31 months (95% CI; 24, 40.5) and the median overall survival (OS) was 38.8 months (95% CI; 29.6, 52.6) from the start of second line treatment. Retreatment with same therapy at relapse significantly reduced TTNT (22 m vs 32.3 m; P = .01) as compared to different therapy; but did not have any impact OS (30.8 m vs 51.1 m; P = .5). In conclusion, this study provides important information about outcomes of patients with AL who require second line treatment for relapsed/refractory disease . Treatment with a different therapy at relapse improves time to next therapy but does not impact OS.
Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism
Mishra, Vivek Kumar , Subramaniam, Malayannan , Kari, Vijayalakshmi, Pitel, Kevin S., Baumgart, Simon J., Naylor, Ryan M. , Nagarajan, Sankari , Ellenrieder, Volker , Hawse, John R. , Johnsen, Steven A. , Wegwitz, Florian , Johnsen, Steven A

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 9 | Pages: 2387-2400

10.1158/0008-5472.can-16-2589 | PMID 28249899 Get It

Abstract TGFβ–SMAD signaling exerts a contextual effect that suppresses malignant growth early in epithelial tumorigenesis but promotes metastasis at later stages. Longstanding challenges in resolving this functional dichotomy may uncover new strategies to treat advanced carcinomas. The Krüppel-like transcription factor, KLF10, is a pivotal effector of TGFβ/SMAD signaling that mediates antiproliferative effects of TGFβ. In this study, we show how KLF10 opposes the prometastatic effects of TGFβ by limiting its ability to induce epithelial-to-mesenchymal transition (EMT). KLF10 depletion accentuated induction of EMT as assessed by multiple metrics. KLF10 occupied GC-rich sequences in the promoter region of the EMT-promoting transcription factor SLUG/SNAI2, repressing its transcription by recruiting HDAC1 and licensing the removal of activating histone acetylation marks. In clinical specimens of lung adenocarcinoma, low KLF10 expression associated with decreased patient survival, consistent with a pivotal role for KLF10 in distinguishing the antiproliferative versus prometastatic functions of TGFβ. Our results establish that KLF10 functions to suppress TGFβ-induced EMT, establishing a molecular basis for the dichotomy of TGFβ function during tumor progression. Cancer Res; 77(9); 2387–400. ©2017 AACR.